Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

BlackRock sets 0.65% fee for new Bitcoin income ETF BITA using covered call strategy.

Market News
10 Jun 2026
Blockonomi
View Source
Bullish
pluang ai news

BlackRock announced a 0.65% annual sponsor fee for its upcoming iShares Bitcoin Premium Income ETF, trading as BITA on Nasdaq. The fund aims to generate income through covered call options primarily based on BlackRock's IBIT ETF, with initial seed capital of $9.9 million and a portfolio including Bitcoin and IBIT shares. Key partners include Goldman Sachs for options clearing, Coinbase and Anchorage for custody, and BNY Mellon for cash management. This launch intensifies competition in the Bitcoin income ETF market, with Goldman Sachs also preparing a similar product potentially approved by July.

More News

Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide

Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide

The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Market News
Neutral
1 hour ago
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.

The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Market News
Bullish
2 hours ago
Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.

The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...

Market News
Bullish
2 hours ago
VINCI launches €200M share buyback program from June 11 to July 31, 2026

VINCI launches €200M share buyback program from June 11 to July 31, 2026

VINCI has initiated a share buyback program by signing an agreement with an investment services provider to repurchase its shares up to a limit of €200 million. The program runs from June 11 to July 31, 2026, with the purchase price capped by shareho...

Company Fundamentals
Bullish
2 hours ago
VINCI launches €200M share buyback program valid until July 31, 2026

VINCI launches €200M share buyback program valid until July 31, 2026

VINCI has initiated a share buyback program by signing an agreement with an investment service provider to repurchase its shares up to a value of €200 million. This program runs from June 11 to July 31, 2026, with purchase prices capped by the genera...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App